When public policy makers make spending decisions about treatments and services for persons with schizophrenia, do they envisage outcomes that are preferred by consumers, families, and clinicians? To investigate this question, Martha Shumway, Ph.D., and her colleagues interviewed 100 policy makers in the state of Florida and 53 consumers, families, and treatment providers. Participants rated the importance of outcomes in six domains: psychotic symptoms, deficit symptoms, side effects of medication, productive activity, daily activity, and social activity. The authors found that policy makers and primary stakeholders have convergent views on some of the major goals of schizophrenia treatment. Both groups valued functional outcomes most highly. However, the policy makers placed significantly less value on improvements in medication side effects, which may make them less likely to allocate funds for widespread use of atypical antipsychotic medications. The authors note that their findings provide a starting point for developing consensus about schizophrenia treatment policies (see page 1124).